Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018227129) SKIN CARE FORMULATIONS AND SKIN CANCER TREATMENT
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

WHAT IS CLAIMED IS:

1. A method for treating a skin cancer condition, the method comprising administering a therapeutically effective amount of a p53-related protein kinase (PRPK) inhibitor to a patient having skin cancer or having a high risk of developing skin cancer.

2. The method of claim 1, wherein the skin cancer condition comprises one or more of actinic keratosis, squamous cell carcinoma, or basal cell carcinoma.

3. The method of claim 1 or 2, wherein the skin cancer condition is associated with T-LAK cell-originated protein kinase (TOPK)-dependent PRPK phosphorylation.

4. The method of any one of claims 1 to 3, further comprising comparing the concentration of phosphorylated PRPK (p-PRPK) in a first biological sample of the patient obtained prior to the administration of the PRPK inhibitor and in a second biological sample of the patient obtained after the administration of the PRPK inhibitor.

5. The method of claim 4, wherein a lower concentration of p-PRPK in the second biological sample compared to the concentration of p-PRPK in the first biological sample is indicative of inhibition of PRPK phosphorylation by the PRPK inhibitor.

6. The method of claim 4 or 5, further comprising adjusting a dosage of the PRPK inhibitor administered to the patient based on the comparison.

7. The method of any one of claims 1 to 6, wherein the patient is administered at least 0.1 mg/day, 1 mg/day, 5 mg/day, 10 mg/day, 20 mg/day, 50 mg/day, or 100 mg/day of the PRPK inhibitor.

8. The method of any one of claims 1 to 7, wherein the PRPK inhibitor comprises one or both of rocuronium bromide or betamethasone 17-valerate, or analogs thereof.

9. The method of any one of claims 1 to 8, wherein the administering the PRPK inhibitor comprises administering a pharmaceutically acceptable carrier including the PRPK inhibitor to the patient.

10. The method of claim 9, wherein the pharmaceutically acceptable carrier comprises a topical formulation including the PRPK inhibitor.

11. The method of any one of claims 1 to 10, further comprising administering at least another treatment comprising one or more of chemotherapy, immunotherapy, radiation therapy, DNA therapy, RNA therapy, nanotherapy, adjuvant therapy, viral therapy, photodynamic therapy, electrocautery, laser therapy, or surgery.

12. The method of any one of claims 1 to 1 1, wherein a therapeutic effect is obtained by administering the PRPK inhibitor, wherein the therapeutic effect comprises one or more of: a reduction or a stability in one or more of an average volume of lesions, an average number of lesions, an average volume of tumors, an average number of tumors, or partial remission, complete remission, or metastasis.

13. A composition comprising a therapeutically effective amount of a PRPK inhibitor for treating a skin cancer condition.

14. The composition of claim 13, wherein the skin cancer condition comprises one or more of actinic keratosis, squamous cell carcinoma, or basal cell carcinoma.

15. The composition of claim 13 or 14, wherein the PRPK inhibitor comprises one or more of a steroid, a steroid derivative, a corticosteroid, or a gonane derivative.

16. The composition of any one of claims 13 to 15, wherein the PRPK inhibitor comprises one or both of rocuronium bromide or betamethasone 17-valerate, or analogs thereof.

17. The composition of any one of claims 13 to 15, wherein the PRPK inhibitor comprises at least one compound having the structure:

where any of Ri to Ri6 = any of H, halo, hydroxy, substituted hydroxy, amino, substituted (acyl, alkyl, aralkyl, heteroaryl, cycloalkyl, aryl) amino, or carbonyl; any of Rn or Ris = any of H, halo, hydroxy, substituted hydroxy, amino, substituted (acyl, alkyl, aralkyl, heteroaryl, cycloalkyl, aryl) amino, or quaternary ammonium group; any of R19 or R20 = H, halo, hydroxy, substituted hydroxy, or substituted (acyl, alkyl, aralkyl,

heteroaryl, cycloalkyl, aryl) amino, or
, wherein Q = H, allyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, hydroxy, substituted hydroxy, amino, substituted (acyl, alkyl, aralkyl, heteroaryl, cycloalkyl, aryl) amino, alkanol, alkenyl, or substituted alkenyl.

18. The composition of claim 17, wherein each of R2, R4, R5, R6, R7, Rs, R9, Rio, R11, R12, Ri4, Ri5, and Ris = H, wherein any of Ri, R3, R7, R13, Ri6, Rn, or R20 = any of H, allyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, sulfonyl, halo, hydroxy, substituted hydroxy, amino, dialkylamino, substituted (acyl, alkyl, aralkyl, heteroaryl, cycloalkyl, aryl) amino, carbonyl, substituted quarternary amino, O-glycosylated, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and wherein R19


= , wherein Q = H, allyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, hydroxy, substituted hydroxy, amino, substituted (acyl, alkyl, aralkyl, heteroaryl, cycloalkyl, aryl) amino, alkanol, alkenyl, or substituted alkenyl.

19. The composition of any one of claims 13 to 18, wherein the composition comprises 0.01%, 0.1%, 1%, 2%, 5%, or 10% (weight/weight) of the PRPK inhibitor.

20. A topical formulation comprising the composition of any one of claims 13 to 19.